We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,014

Life sciences & medical technology newsletter, Fall 2013 - Winter 2014
  • Greenberg Traurig LLP
  • USA
  • January 10 2014

On September 25, 2013, the U.S. Food and Drug Administration (the "FDA") released final guidance on the regulatory requirements regarding the


Patenting business methods after Mayo
  • Foley & Lardner LLP
  • USA
  • July 30 2012

Advances in information technology, such as high-performance computing, enables the collection, analysis and sharing of information between patients and medical providers


Control at issue in split Federal Circuit ruling on joint infringement
  • Shook Hardy & Bacon LLP
  • USA
  • April 21 2011

A divided Federal Circuit Court of Appeals panel, relying on recent precedent, has confirmed that "where the actions of multiple parties combine to perform every step of a claimed method, the claim is directly infringed only if one party exercises 'control or direction' over the entire process such that every step is attributable to the controlling party."


Evaluating life sciences inventions: surveying patents similar to assessing real estate
  • Pillsbury Winthrop Shaw Pittman LLP
  • USA
  • March 29 2011

Pillsbury Life Sciences team co-head Dr. John Wetherell explains why evaluating the worth of intangible IP in this sector is not all that different from assessing the value of real property


CAFC weekly: November 5, 2010
  • Burns & Levinson LLP
  • USA
  • November 10 2010

After two weeks of not handing down precedential opinions, this week the CAFC provided us with a split decision on denial of en banc review, an opinion affirming a grant of a preliminary injunction, as well as an opinion presenting an example of the usefulness of "Beauregard" claims, which are claims in which software is claimed by claiming the storage medium having the computer code embodied therein


Noteworthy cases in the United States Supreme Court’s 2011 term
  • Larkin Hoffman
  • USA
  • September 21 2011

The first Monday in October represents the start of a new term for the United States Supreme Court


Claims in salbutamol complaint are adequately pled
  • Morris James LLP
  • USA
  • March 30 2016

The disputed technology relates to processes for making optically pure (R) and (S) salbutamol. Defendant moves to dismiss claims of induced


Copyright for Engineered DNA (Part 2)
  • GQ Life Sciences
  • USA
  • March 1 2016

With the United States Supreme Court ruling in Myriad, the enforceability of certain claims in existing gene patents and the broader patentability of


Patent Cases Pending Before the Supreme Court (October Term)
  • Shearman & Sterling LLP
  • USA
  • August 19 2016

On March 21, 2016, the Supreme Court granted Samsung’s petition for a writ of certiorari as to the following question: Where a design patent is


Federal Circuit Limits the Safe Harbor Provision and the Scope of 271(g)
  • McDermott Will & Emery
  • USA
  • December 23 2015

Addressing issues of infringement under 35 U.S.C. 271(g) and the safe harbor provision of 271(e), the U.S. Court of Appeals for the Federal